The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.
Andres Cervantes-Ruiperez
Consultant or Advisory Role - Genentech
Dejan Juric
No relevant relationships to disclose
Manuel Hidalgo
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Genentech
George R. Blumenschein
Consultant or Advisory Role - Genentech
Research Funding - Genentech
José Baselga
Consultant or Advisory Role - Genentech
Desamparados Roda Perez
No relevant relationships to disclose
Rodrigo Dienstmann
No relevant relationships to disclose
Antonio Calles
No relevant relationships to disclose
Antonio Jimeno
No relevant relationships to disclose
Sandra Sanabria
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Catherine Littman
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Lukas C. Amler
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Andrea Pirzkall
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Josep Tabernero
Consultant or Advisory Role - Genentech